Physician profile
Christopher A Waynick
NPI 1780819375
$13,873.79
in general payments reported to CMS, 2019-2025
66 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,895 · 2020: $569 · 2021: $213 · 2022: $454 · 2023: $1,577 · 2024: $1,308 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,643 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,642.67 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,538.04 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Bayer Healthcare Pharmaceuticals INC. | $1,919.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $840.98 | 2019-2025 | Tagrisso, Lynparza, Imfinzi |
| Novartis Pharmaceuticals Corporation | $610.39 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $598.25 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Celgene Corporation | $448.12 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
| E.R. Squibb & Sons, L.L.C. | $425.83 | 2019-2025 | Opdivo, Opdualag |
| Regeneron Healthcare Solutions, INC. | $360.64 | 2019-2025 | Libtayo |
| Genentech USA, INC. | $338.30 | 2019-2024 | Columvi, Polivy, Lunsumio |
| Genzyme Corporation | $297.80 | 2019-2025 | |
| Eisai INC. | $266.21 | 2019-2025 | |
| Amgen INC. | $259.42 | 2019-2020 | |
| Incyte Corporation | $253.31 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Exelixis INC. | $247.17 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $234.05 | 2019-2025 | Xtandi, Padcev |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Waynick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.